Isomorphic Labs
An artificial intelligence company to discover new drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Corporate spinout | |
* | $600m | Late VC | |
| Total Funding | $600m | ||
| GBP | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Isomorphic Labs, founded in 2021, is an AI-driven company dedicated to revolutionizing drug discovery and development. By leveraging the groundbreaking advancements from Google DeepMind, such as AlphaFold, Isomorphic Labs aims to apply machine learning and computational methods to tackle complex biological challenges. The company operates at the intersection of AI, biotechnology, and medicine, focusing on developing predictive and generative models to enhance the efficiency and effectiveness of drug design and medical research.
Supported by the robust infrastructure of Alphabet Inc., Isomorphic Labs combines the agility of a startup with substantial resources and expertise. The leadership team, including notable figures like Sir Demis Hassabis and Colin Murdoch, drives the company's mission to transform how medicine is discovered and delivered. Their approach integrates deep learning, reinforcement learning, and other advanced AI techniques to innovate within the life sciences, aiming to bring better therapeutic solutions to market more swiftly and accurately.